CEO's $3.6M Insider Buy and High Short Interest Create Squeeze Risk, but Hepatotoxicity Overhang Keeps INBX a WAIT

What happened

Inhibrx Biosciences' stock traded at $97.93 on October 1, 2026, with the CEO deploying over $3.6 million in personal funds to buy shares after a clinical outperformance that the market sold off. The purchase accompanies a 28% short interest in the public float, setting up conditions for a potential short squeeze as an FDA approval date for ozekibart (INBRX-109) approaches. However, the DeepValue master report flags that timeline credibility is tightly coupled to hepatotoxicity management, following a prior Grade 5 hepatic failure event and a treatment-related hepatic AE imbalance (11.8% vs 4.5% placebo). Financially, the company remains pre-revenue with $153.1 million cash as of September 2025 and significant pre-commercialization spending ahead, leaving limited margin of safety if the BLA slips. The insider buy is a positive signal on management's conviction, but it does not eliminate the binary regulatory risk that dominates the investment case.

Implication

The high short interest and insider buying could drive a short-term squeeze, but such moves are often violent and unpredictable, favoring traders over long-term investors. The core investment thesis still rests on a clean FDA submission by Q2 2026 (now likely occurring in 2026) and manageable liver-safety review, which remains uncertain given the prior partial clinical hold. With the stock trading above $95, the DeepValue framework suggests trimming rather than adding, as the Bull scenario ($120) is only positioned if label expansion and CRC durability strengthen. The Bear scenario ($45) remains plausible if FDA requests additional liver-safety analyses, causing BLA timing to slip into 2H 2026. Maintain a disciplined approach: wait for a filing-readiness signal or a pullback toward the $60 attractive entry before considering new positions.

Thesis delta

The thesis remains WAIT, but insider buying introduces a near-term squeeze catalyst that may temporarily push the stock above fair value. However, the fundamental risk from hepatotoxicity and the >$95 price level reinforce the trim recommendation rather than changing the medium-term outlook.